levomepromazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1752 60-99-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methotrimeprazine
  • hirnamin
  • levomeprazine
  • levomepromazin
  • levopromazine
  • levoprome
  • levopromethazine
  • levotomin
  • mepromazine
  • levomepromazine
  • levomepromazine maleate
  • methotrimeprazine hydrochloride
  • nozinan
A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
  • Molecular weight: 328.47
  • Formula: C19H24N2OS
  • CLOGP: 5.03
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 15.71
  • ALOGS: -4.80
  • ROTB: 5

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.10 g P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.90 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
None FDA IMMUNEX

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional overdose 274.65 23.44 141 6619 74011 63408251
Somnolence 177.95 23.44 149 6611 178536 63303726
Intentional self-injury 173.16 23.44 74 6686 25613 63456649
Drug interaction 128.24 23.44 139 6621 228992 63253270
Toxicity to various agents 126.34 23.44 143 6617 247107 63235155
Electrocardiogram QT prolonged 107.19 23.44 71 6689 59459 63422803
Excessive eye blinking 100.28 23.44 24 6736 1256 63481006
Extrapyramidal disorder 98.57 23.44 41 6719 13243 63469019
Urinary retention 82.27 23.44 47 6713 30254 63452008
Neuroleptic malignant syndrome 82.07 23.44 35 6725 12021 63470241
Sopor 81.40 23.44 42 6718 22122 63460140
Drug abuse 77.19 23.44 63 6697 72455 63409807
Altered state of consciousness 73.54 23.44 41 6719 25189 63457073
Suicide attempt 60.80 23.44 51 6709 60867 63421395
Biliary tract infection 49.03 23.44 12 6748 690 63481572
Poisoning deliberate 46.26 23.44 23 6737 11195 63471067
Depressed level of consciousness 46.12 23.44 44 6716 62034 63420228
Cholangitis infective 45.52 23.44 10 6750 356 63481906
Aggression 39.77 23.44 27 6733 23471 63458791
Hallucination, auditory 37.79 23.44 21 6739 12803 63469459
Product use in unapproved indication 37.71 23.44 68 6692 179012 63303250
Mental disorder 37.38 23.44 27 6733 25892 63456370
Bacillus infection 37.11 23.44 10 6750 843 63481419
Hyperprolactinaemia 35.68 23.44 14 6746 3886 63478376
Vascular pain 33.21 23.44 9 6751 775 63481487
Asphyxia 32.57 23.44 15 6745 6166 63476096
Flat affect 31.87 23.44 10 6750 1440 63480822
Psychiatric symptom 31.73 23.44 14 6746 5209 63477053
Hypothermia 31.41 23.44 19 6741 13562 63468700
Tension 31.18 23.44 12 6748 3163 63479099
Illusion 30.44 23.44 9 6751 1061 63481201
Overdose 29.89 23.44 48 6712 115030 63367232
Perforation 29.55 23.44 9 6751 1174 63481088
Diabetic hyperosmolar coma 29.30 23.44 7 6753 363 63481899
Withdrawal syndrome 29.22 23.44 21 6739 19976 63462286
Galactorrhoea 28.06 23.44 12 6748 4143 63478119
Pulmonary embolism 28.05 23.44 47 6713 116637 63365625
Disinhibition 27.65 23.44 8 6752 875 63481387
Behaviour disorder 27.57 23.44 11 6749 3188 63479074
Intestinal obstruction 27.01 23.44 24 6736 30875 63451387
Blood prolactin increased 26.61 23.44 11 6749 3492 63478770
Muscle rigidity 26.36 23.44 16 6744 11484 63470778
Agitation 26.10 23.44 32 6728 59725 63422537
Schizophrenia 25.83 23.44 15 6745 9937 63472325
Psychomotor retardation 25.55 23.44 11 6749 3859 63478403
Bradykinesia 25.50 23.44 12 6748 5176 63477086
Respiratory acidosis 25.43 23.44 13 6747 6702 63475560
Depressed mood 25.23 23.44 26 6734 40165 63442097
Seizure 24.93 23.44 48 6712 132586 63349676
Partial seizures with secondary generalisation 23.54 23.44 6 6754 407 63481855
Antipsychotic drug level increased 23.46 23.44 10 6750 3425 63478837

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 164.41 24.70 77 6791 17857 34932206
Drug abuse 137.20 24.70 130 6738 98966 34851097
Intentional self-injury 110.56 24.70 54 6814 13717 34936346
Extrapyramidal disorder 104.88 24.70 51 6817 12829 34937234
Suicide attempt 97.08 24.70 72 6796 39044 34911019
Toxicity to various agents 79.02 24.70 141 6727 200221 34749842
Dystonic tremor 78.76 24.70 16 6852 203 34949860
Sopor 78.12 24.70 41 6827 12095 34937968
Drug interaction 75.40 24.70 148 6720 225798 34724265
Dystonia 70.83 24.70 37 6831 10808 34939255
Intestinal haemorrhage 69.21 24.70 26 6842 3470 34946593
Blood glucose fluctuation 69.04 24.70 27 6841 4017 34946046
Acute pulmonary oedema 65.60 24.70 31 6837 7312 34942751
Blood creatine phosphokinase increased 60.27 24.70 58 6810 44799 34905264
Intentional overdose 57.79 24.70 56 6812 43618 34906445
Psychomotor hyperactivity 57.67 24.70 31 6837 9591 34940472
Cognitive disorder 56.32 24.70 46 6822 28647 34921416
Blood glucose abnormal 55.86 24.70 26 6842 5926 34944137
Electrocardiogram QT prolonged 55.11 24.70 53 6815 40899 34909164
Altered state of consciousness 52.00 24.70 40 6828 22853 34927210
Restlessness 48.22 24.70 40 6828 25442 34924621
Wrong patient received product 46.29 24.70 18 6850 2636 34947427
Feelings of worthlessness 45.92 24.70 11 6857 308 34949755
Abulia 43.60 24.70 12 6856 588 34949475
Parkinsonism 42.65 24.70 24 6844 8114 34941949
Sudden death 42.25 24.70 30 6838 15171 34934892
Sedation 41.89 24.70 34 6834 20972 34929091
Miosis 41.69 24.70 25 6843 9510 34940553
Somnolence 40.85 24.70 76 6792 111040 34839023
Dyspnoea 38.69 24.70 13 6855 376769 34573294
Rhabdomyolysis 37.64 24.70 56 6812 68107 34881956
Victim of chemical submission 37.49 24.70 7 6861 55 34950008
Gastrointestinal hypermotility 37.08 24.70 8 6860 138 34949925
Electrocardiogram QT shortened 36.66 24.70 8 6860 146 34949917
Urinary incontinence 36.48 24.70 30 6838 18844 34931219
Wrong schedule 35.24 24.70 8 6860 176 34949887
Schizophrenia 33.49 24.70 21 6847 8645 34941418
Drug screen false positive 32.48 24.70 10 6858 729 34949334
Aggression 32.23 24.70 39 6829 38925 34911138
Restless legs syndrome 31.67 24.70 20 6848 8334 34941729
Contraindicated product administered 31.16 24.70 29 6839 21452 34928611
Obsessive-compulsive disorder 30.76 24.70 17 6851 5547 34944516
Hyperhidrosis 30.62 24.70 54 6814 75638 34874425
Confusional state 30.55 24.70 79 6789 144081 34805982
Therapeutic product effect incomplete 30.03 24.70 43 6825 50498 34899565
Balance disorder 29.32 24.70 38 6830 40616 34909447
Mumps 29.19 24.70 6 6862 81 34949982
Salivary hypersecretion 28.60 24.70 19 6849 8625 34941438
Depressed level of consciousness 27.76 24.70 38 6830 42803 34907260
Respiratory depression 27.64 24.70 24 6844 16221 34933842
Coma 27.34 24.70 39 6829 45639 34904424
Overdose 27.05 24.70 57 6811 91002 34859061
Haematoma 26.87 24.70 29 6839 25576 34924487
Product administration error 25.52 24.70 23 6845 16321 34933742
Neurological decompensation 24.89 24.70 12 6856 2954 34947109

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 244.87 20.82 109 12723 27450 79704106
Intentional overdose 216.09 20.82 160 12672 105800 79625756
Intentional self-injury 189.14 20.82 96 12736 32323 79699233
Somnolence 184.40 20.82 209 12623 238772 79492784
Drug abuse 182.61 20.82 174 12658 162517 79569039
Extrapyramidal disorder 164.71 20.82 78 12754 22601 79708955
Drug interaction 156.11 20.82 256 12576 414927 79316629
Sopor 147.96 20.82 82 12750 32928 79698628
Suicide attempt 144.28 20.82 114 12718 82818 79648738
Toxicity to various agents 141.31 20.82 247 12585 421293 79310263
Electrocardiogram QT prolonged 121.41 20.82 107 12725 90279 79641277
Altered state of consciousness 107.19 20.82 74 12758 43748 79687808
Dystonic tremor 81.94 20.82 16 12816 203 79731353
Blood creatine phosphokinase increased 78.41 20.82 73 12759 66017 79665539
Psychomotor hyperactivity 73.13 20.82 41 12791 16808 79714748
Excessive eye blinking 70.43 20.82 21 12811 1680 79729876
Aggression 69.72 20.82 61 12771 50897 79680659
Dystonia 66.55 20.82 42 12790 21357 79710199
Depressed level of consciousness 61.87 20.82 77 12755 96575 79634981
Wrong patient received product 56.71 20.82 23 12809 4595 79726961
Psychiatric symptom 56.64 20.82 26 12806 7009 79724547
Restlessness 52.53 20.82 50 12782 46442 79685114
Acute pulmonary oedema 49.50 20.82 30 12802 14200 79717356
Intestinal haemorrhage 49.40 20.82 23 12809 6403 79725153
Poisoning deliberate 48.87 20.82 33 12799 18795 79712761
Sudden death 48.05 20.82 35 12797 22476 79709080
Overdose 46.63 20.82 96 12736 184110 79547446
Urinary retention 46.01 20.82 51 12781 56579 79674977
Coma 45.86 20.82 68 12764 100581 79630975
Pneumonia aspiration 43.88 20.82 54 12778 66913 79664643
Akathisia 43.69 20.82 27 12805 13232 79718324
Schizophrenia 42.33 20.82 28 12804 15412 79716144
Feelings of worthlessness 42.10 20.82 11 12821 541 79731015
Substance abuse 41.34 20.82 24 12808 10502 79721054
Rhabdomyolysis 40.43 20.82 65 12767 103066 79628490
Muscle rigidity 40.38 20.82 30 12802 19852 79711704
Salivary hypersecretion 39.49 20.82 26 12806 14198 79717358
Cognitive disorder 37.39 20.82 51 12781 69875 79661681
Hypothermia 36.80 20.82 30 12802 22716 79708840
Blood glucose fluctuation 36.65 20.82 19 12813 6663 79724893
Agitation 36.59 20.82 61 12771 99654 79631902
Depressed mood 36.55 20.82 42 12790 48438 79683118
Biliary tract infection 36.04 20.82 12 12820 1376 79730180
Parkinsonism 35.88 20.82 26 12806 16558 79714998
Sedation 35.87 20.82 43 12789 51852 79679704
Abulia 35.42 20.82 11 12821 1009 79730547
Rash 35.39 20.82 25 12807 578333 79153223
Ileus paralytic 35.32 20.82 21 12811 9599 79721957
Cholangitis infective 35.31 20.82 10 12822 667 79730889
Blood glucose abnormal 33.50 20.82 21 12811 10545 79721011
Obsessive-compulsive disorder 32.93 20.82 17 12815 5910 79725646
Pain 31.83 20.82 40 12792 703762 79027794
Wrong schedule 31.29 20.82 8 12824 361 79731195
Arthralgia 30.86 20.82 28 12804 571775 79159781
Drug screen false positive 30.44 20.82 10 12822 1099 79730457
Intestinal obstruction 30.31 20.82 36 12796 42984 79688572
Bacillus infection 30.04 20.82 10 12822 1145 79730411
Mania 29.36 20.82 24 12808 18236 79713320
Mental disorder 28.59 20.82 30 12802 31272 79700284
Joint swelling 28.23 20.82 6 12826 288640 79442916
Hallucination 28.23 20.82 50 12782 85695 79645861
Vascular pain 28.17 20.82 9 12823 906 79730650
Miosis 28.05 20.82 22 12810 15767 79715789
Hyperprolactinaemia 27.69 20.82 14 12818 4662 79726894
Asthenia 27.67 20.82 25 12807 511664 79219892
Colitis ischaemic 26.42 20.82 21 12811 15338 79716218
Behaviour disorder 26.41 20.82 15 12817 6298 79725258
Hyperhidrosis 26.21 20.82 68 12764 151424 79580132
Product use in unapproved indication 26.04 20.82 94 12738 250265 79481291
Tachycardia 25.98 20.82 75 12757 177693 79553863
Tremor 25.09 20.82 72 12760 170011 79561545
Cough 24.96 20.82 14 12818 366775 79364781
Abnormal behaviour 24.87 20.82 30 12802 36391 79695165
Deep vein thrombosis 24.86 20.82 58 12774 120861 79610695
Galactorrhoea 24.81 20.82 12 12820 3634 79727922
Asphyxia 24.50 20.82 18 12814 11702 79719854
Perforation 24.26 20.82 9 12823 1417 79730139
Neuroleptic-induced deficit syndrome 23.31 20.82 4 12828 23 79731533
Seizure 23.23 20.82 75 12757 188759 79542797
Confusional state 23.22 20.82 107 12725 317890 79413666
Therapeutic product effect incomplete 22.90 20.82 62 12770 141583 79589973
Tension 22.67 20.82 12 12820 4392 79727164
Eosinophilia 22.63 20.82 32 12800 45313 79686243
Illusion 22.51 20.82 9 12823 1732 79729824
Megacolon 22.28 20.82 11 12821 3484 79728072
Restless legs syndrome 21.54 20.82 21 12811 20071 79711485
Withdrawal syndrome 21.49 20.82 24 12808 26830 79704726
Psychomotor retardation 21.41 20.82 13 12819 6171 79725385
Disturbance in attention 21.25 20.82 33 12799 50768 79680788
Diabetic hyperosmolar coma 21.13 20.82 7 12825 790 79730766
Flat affect 21.13 20.82 9 12823 2032 79729524
Hallucination, auditory 21.02 20.82 21 12811 20672 79710884
Blood prolactin increased 20.84 20.82 11 12821 4000 79727556

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AA02 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with aliphatic side-chain
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018689 Sensory System Agents
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drugs
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:48873 acetylcholine receptor antagonist
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors
CHEBI has role CHEBI:149553 anticoronaviral drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 4.55 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR Ki 9.24 PDSP
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.02 CHEMBL

External reference:

IDSource
4018915 VUID
N0000147208 NUI
D00403 KEGG_DRUG
4018915 VANDF
CHEBI:6838 CHEBI
CHEMBL1764 ChEMBL_ID
CHEMBL1725730 ChEMBL_ID
C017901 MESH_SUPPLEMENTAL_RECORD_UI
7603 IUPHAR_LIGAND_ID
705 INN_ID
7104-38-3 SECONDARY_CAS_RN
DB01403 DRUGBANK_ID
9G0LAW7ATQ UNII
160372 RXNORM
1834 MMSL
5078 MMSL
d00814 MMSL
001581 NDDF
004134 NDDF
005070 NDDF
387509007 SNOMEDCT_US
395790003 SNOMEDCT_US
57911003 SNOMEDCT_US
89029005 SNOMEDCT_US
C0025678 UMLSCUI
D008728 MESH_DESCRIPTOR_UI
CHEMBL2104973 ChEMBL_ID
72287 PUBCHEM_CID

Pharmaceutical products:

None